Omicron BA.4.6 Makes Up around 14% COVID-19 Variants, US CDC

Healthcare

The US Centers for Disease Control and Prevention (CDC) estimated that nearly 14 percent of the circulating COVID-19 variants in the United States were of BA.4.6 subvariant of Omicron. The Omicron BA.4.6 subvariant is expected to account for around 13.6 percent of total COVID-19 cases in the United States, which is higher than the prevalence of 12.7 percent.

The BA.4.6 subvariant has been found to be better at evading COVID-19 antibody therapies, and with the US FDA warning healthcare providers that Evusheld of AstraZeneca had the risk of being ineffective against some COVID-19 variants it cannot neutralize.

According to the US FDA fact sheet, the BA.4.6 subvariant was likely to have an over 1,000-fold reduction in susceptibility to the antibody therapy, which was based on the laboratory tests. The BA.4.6 subvariant is increasing in prevalence across the United States, even as the Omicron BA.5 subvariant remains the dominant strain with 79.2 percent of the COVID-19 cases.

See also  UK To Donate One Million AstraZeneca Covid-19 Vaccine to Bangladesh

Both BA.4 and BA.5 subvariants have been driving a surge in new infections globally. Recently, the United States has started administration of COVID-19 vaccine boosters specifically retooled for targeting both the subvariants.

Sandy

Writing is a medium to express feelings and convey facts. A creative mind never rests in peace and this amazing platform gives me the freedom to write about what I like most.

I’ve been a writer/blogger for the last twelve years and have covered technology-related topics. However, I also have considerable years of experience in writing for various domains – Technology, Beauty, Fashion, Pharmaceutical, human psychology etc. Technology is my forte.

I’ve handled many interesting projects. Writing is my passion. As an author, I’ve learned a lot in my long journey of penning down my thoughts!